Viatris led the way in the US respiratory space once again last summer, debuting generic competition to AstraZeneca’s Symbicort (budesonide/formoterol) following years of patent-litigation action over the inhaler brand’s intellectual property.
Viatris: Symbicort Market Shaping ‘Exactly The Way We Thought’
Firm Debuted First Generic To Major COPD Brand Last Summer
Although transitioning from its generics foundations, Viatris still has interests in certain complex products. The firm spoke about one, its Breyna generic version of Symbicort, at the recent J.P. Morgan Annual Healthcare Conference.
More from Generics
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.